Differential effects of aripiprazole on D2, 5-HT2, and 5-HT1A receptor occupancy in patients with schizophrenia: A triple tracer PET study

American Journal of Psychiatry

Volumn 164, Issue 9, 2007, Pages 1411-1417

  Mamo, David ^a   Graff, Ariel ^b   Mizrahi, Romina ^b   Shammi, C M ^b   Romeyer, Françoise ^b   Kapur, Shitij ^b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DEHYDROARIPIPRAZOLE; DOPAMINE 2 RECEPTOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE C 11; NEUROLEPTIC AGENT; OLANZAPINE; RACLOPRIDE C 11; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2 RECEPTOR; SETOPERONE F 18; TRACER; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; INSOMNIA; MALE; MUSCLE TONE; NAUSEA; NIGHTMARE; NIGRONEOSTRIATAL SYSTEM; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RESTLESSNESS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; SLEEP DISORDER;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA; BASAL GANGLIA DISEASES; CARBON RADIOISOTOPES; CAUDATE NUCLEUS; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PSYCHOTIC DISORDERS; PUTAMEN; PYRIDINES; PYRIMIDINONES; QUINOLONES; RACLOPRIDE; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 34648830603     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.2007.06091479     Document Type: Article

References (38)

1. 2 receptors. J Pharmacol Exp Ther 2002; 302:381-389
2. 2S receptors render it a unique antipsychotic. Eur J Pharmacol 2005; 515:10-19
3. Inoue T, Domae M, Yamada K, Furukawa T: Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4- dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 1996; 277:137-143
4. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mailman RB: Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999; 20:612-627
5. Arnt J, Skarsfeldt T: Do novel antipsychotics have similar pharmacological characteristics? a review of the evidence. Neuropsychopharmacology 1998; 18:63-101
6. 2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 2006; 31:1854-1863
7. 1A receptor. Eur J Pharmacol 2002; 441:137-140
8. Meltzer HY, Matsubara S, Lee JC: The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989; 25:390-392
9. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW: Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63:763-771
10. 11C] raclopride. Neuropsychopharmacology 2002; 27:248-259
11. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59(suppl 20):22-33
12. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276
13. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 218-222
14. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
15. Barnes TRE: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676
16. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 534-537
17. 11C]M100907. Synapse 2000; 38:421-431
18. 2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 1994; 11:245-256
19. 18F-labeled setoperone. J Neurochem 1990; 54:1744-1754
20. Rusjan P, Mamo D, Ginovart N, Hussey D, Vitcu I, Yasuno F, Tetsuya S, Houle S, Kapur S: An automated method for the extraction of regional data from PET images. Psychiatry Res 2006; 147:79-89
21. 2 receptor increase in PET study of schizophrenia. Arch Gen Psychiatry 1987; 44:671-672
22. 1A receptor in schizophrenia and during clozapine treatment. J Psychopharmacol 2004; 18:346-354
23. 2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. Schizophr Res 1998; 31:13-17
24. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ: A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984; 15:217-227
25. Ichise M, Meyer JH, Yonekura Y: An introduction to PET and SPECT neuroreceptor quantification models. J Nucl Med 2001; 42:755-763
26. 11C]WAY-100635 in humans: comparison of arterial and reference tissue input functions. J Cereb Blood Flow Metab 2000; 20:1111-1133
27. Lammertsma AA, Hume SP: Simplified reference tissue model for PET receptor studies. Neuroimage 1996; 4:153-158
28. 11C-metomidate PET imaging of adrenocortical cancer. Eur J Nucl Med Mol Imaging 2003; 30:403-410
29. Millan MJ, Brocco M, Veiga S, Cistarelli L, Melon C, Gobert A: WAY 100,635 enhances both the "antidepressant" actions of duloxetine and its influence on dialysate levels of serotonin in frontal cortex. Eur J Pharmacol 1998; 341:165-167
30. 1A receptors. J Pharmacol Exp Ther 2000; 295:853-861
31. Meller E, Goldstein M, Bohmaker K: Receptor reserve for 5-hydroxytryptamine 1A-mediated inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5-hydroxytryptamine 1A agonists. Mol Pharmacol 1990; 37:231-237
32. Nash JF, Meltzer HY: Effect of gepirone and ipsapirone on the stimulated and unstimulated secretion of prolactin in the rat. J Pharmacol Exp Ther 1989; 249:236-241
33. 11C]raclopride. J Psychopharmacol 2002; 16:195-199
34. Scaramellini C, Leff P: A three-state receptor model: predictions of multiple agonist pharmacology for the same receptor type. Ann N Y Acad Sci 1998; 861:97-103
35. Leff P: The two-state model of receptor activation. Trends Pharmacol Sci 1995; 16:89-97
36. 1A receptors: affinity, efficacy, and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol 2005; 8:341-356
37. 1A receptor activation in attenuation of catalepsy induction in rats. Neuropharmacology 2005; 49:135-143
38. Assie MB, Ravailhe V, Faucillon V, Newman-Tancredi A: Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther 2005; 315:265-272